B-intervention	0	8	Propolis
O	9	11	in
O	12	15	the
O	16	26	prevention
O	27	29	of
B-condition	30	34	oral
I-condition	35	44	mucositis
O	45	47	in
O	48	54	breast
O	55	61	cancer
O	62	70	patients
O	71	80	receiving
O	81	89	adjuvant
O	90	102	chemotherapy
O	102	103	:
O	104	105	A
O	106	111	pilot
O	112	122	randomised
O	123	133	controlled
O	134	139	trial
O	139	140	.

O	141	146	Chemo
O	146	147	-
O	147	154	induced
O	155	159	oral
O	160	169	mucositis
O	170	171	(
O	171	173	OM
O	173	174	)
O	175	177	is
O	178	188	associated
O	189	193	with
O	194	205	significant
O	206	214	symptoms
O	214	215	,
O	216	225	treatment
O	226	232	delays
O	233	236	and
O	237	246	increased
O	247	252	costs
O	252	253	.

O	254	258	This
O	259	264	pilot
O	265	275	randomised
O	276	286	controlled
O	287	292	trial
O	293	298	aimed
O	299	301	at
O	302	312	evaluating
O	313	316	the
O	317	323	safety
O	323	324	,
O	325	337	tolerability
O	338	341	and
O	342	352	compliance
O	353	357	with
O	358	366	propolis
O	367	369	in
B-eligibility	370	376	breast
I-eligibility	377	383	cancer
I-eligibility	384	392	patients
I-eligibility	393	402	receiving
I-eligibility	403	414	doxorubicin
I-eligibility	415	418	and
I-eligibility	419	435	cyclophosphamide
O	435	436	,
O	437	444	testing
O	445	456	preliminary
O	457	465	clinical
O	466	474	efficacy
O	475	477	of
O	478	486	propolis
O	487	489	in
O	490	493	the
O	494	504	prevention
O	505	507	of
O	508	510	OM
O	510	511	,
O	512	515	and
O	516	529	prospectively
O	530	540	evaluating
O	541	544	the
O	545	554	incidence
O	555	557	of
O	558	560	OM
O	560	561	.

B-total-participants	562	567	Sixty
O	568	576	patients
O	577	581	were
O	582	592	randomised
O	593	595	to
O	596	603	receive
O	604	610	either
O	611	612	a
O	613	616	dry
O	617	624	extract
O	625	627	of
O	628	636	propolis
O	637	641	with
O	642	643	8
O	643	644	%
O	644	645	-
O	645	647	12
O	647	648	%
O	649	651	of
O	652	660	galangin
O	661	665	plus
O	666	671	mouth
O	672	679	rinsing
O	680	684	with
O	685	691	sodium
O	692	703	bicarbonate
O	704	705	(
O	705	717	experimental
O	718	721	arm
O	721	722	)
O	722	723	,
O	724	726	or
B-control	727	732	mouth
I-control	733	740	rinsing
I-control	741	745	with
I-control	746	752	sodium
I-control	753	764	bicarbonate
I-control	765	766	(
I-control	766	773	control
I-control	774	777	arm
I-control	777	778	)
O	778	779	.

O	780	782	OM
O	783	786	was
O	787	796	evaluated
O	797	801	with
O	802	805	the
O	806	809	NCI
O	809	810	-
O	810	815	CTCAE
O	816	818	v4
O	818	819	.
O	819	820	0
O	821	826	after
O	827	828	5
O	828	829	,
O	830	832	10
O	832	833	,
O	834	836	15
O	837	840	and
O	841	843	21
O	844	848	days
O	849	851	of
O	852	861	treatment
O	861	862	.

O	863	873	Compliance
O	874	878	with
O	878	879	,
O	880	892	tolerability
O	893	895	of
O	896	904	propolis
O	905	908	and
O	909	916	adverse
O	917	923	events
O	924	928	were
O	929	937	recorded
O	937	938	.

O	939	942	The
O	943	952	incidence
O	953	955	of
O	956	958	OM
O	959	962	was
O	963	967	also
O	968	981	prospectively
O	982	991	evaluated
O	992	995	for
O	996	997	6
O	998	1004	months
O	1004	1005	.

O	1006	1009	Two
O	1010	1018	patients
O	1019	1020	(
O	1020	1021	6
O	1021	1022	.
O	1022	1023	7
O	1023	1024	%
O	1024	1025	)
O	1026	1036	manifested
O	1037	1038	a
O	1039	1048	suspected
B-outcome	1049	1053	skin
I-outcome	1054	1062	reaction
I-outcome	1063	1065	to
I-outcome	1066	1074	propolis
O	1074	1075	.

B-iv-bin-abs	1076	1078	No
O	1079	1086	patient
O	1087	1089	in
O	1090	1093	the
O	1094	1106	experimental
O	1107	1110	arm
O	1111	1120	developed
B-outcome	1121	1123	OM
I-outcome	1124	1125	>
I-outcome	1126	1128	G1
O	1128	1129	,
O	1130	1135	while
O	1136	1138	in
O	1139	1142	the
O	1143	1150	control
O	1151	1154	arm
O	1155	1157	OM
O	1158	1159	>
O	1160	1162	G1
O	1163	1166	was
B-cv-bin-percent	1167	1169	16
I-cv-bin-percent	1169	1170	.
I-cv-bin-percent	1170	1171	7
I-cv-bin-percent	1171	1172	%
O	1173	1174	(
O	1174	1175	p
O	1176	1177	=
O	1178	1179	.
O	1179	1181	02
O	1181	1182	)
O	1182	1183	.

O	1184	1187	The
B-outcome	1188	1197	incidence
I-outcome	1198	1200	of
I-outcome	1201	1203	OM
I-outcome	1204	1205	â‰¥
I-outcome	1206	1208	G1
O	1209	1211	at
O	1212	1215	the
O	1216	1219	end
O	1220	1222	of
O	1223	1229	cycles
O	1230	1231	2
O	1231	1232	-
O	1232	1233	8
O	1234	1237	was
O	1238	1244	higher
O	1245	1247	at
O	1248	1251	the
O	1252	1258	second
O	1259	1260	(
O	1260	1262	25
O	1262	1263	%
O	1263	1264	)
O	1265	1268	and
O	1269	1274	fifth
O	1275	1281	cycles
O	1282	1283	(
O	1283	1285	45
O	1285	1286	.
O	1286	1287	8
O	1287	1288	%
O	1288	1289	)
O	1289	1290	.

O	1291	1299	Propolis
O	1300	1304	plus
O	1305	1316	bicarbonate
O	1317	1320	was
B-outcome	1321	1325	safe
O	1325	1326	,
B-outcome	1327	1331	well
I-outcome	1332	1341	tolerated
O	1342	1345	and
B-outcome	1346	1357	promisingly
I-outcome	1358	1367	effective
O	1368	1370	in
O	1371	1374	the
O	1375	1385	prevention
O	1386	1388	of
O	1389	1391	OM
O	1392	1394	in
O	1395	1403	patients
O	1404	1408	with
O	1409	1415	breast
O	1416	1422	cancer
O	1422	1423	.
